35 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not yet completed an ownership change … analysis. If a requisite ownership change occurs, the amount of remaining tax attribute carryforwards available to offset taxable income and reduce
424B5
TARS
Tarsus Pharmaceuticals Inc
1 Mar 24
Prospectus supplement for primary offering
5:17pm
income tax treaty, which may be offset by U.S. source capital losses of such non-U.S. holder, if any, provided the non-U.S. holder has timely filed
424B5
TARS
Tarsus Pharmaceuticals Inc
29 Feb 24
Prospectus supplement for primary offering
5:08pm
gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source
8-K
EX-99.1
TARS
Tarsus Pharmaceuticals Inc
26 Feb 24
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
9:18pm
program spend for TP-05, and $0.6 million of increased spend for other early-stage programs. The increase was partially offset by decreases of $6.1
8-K
EX-99.1
61ufz314
9 Nov 23
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
4:05pm
424B5
os8l zcfgz37ew3h
2 Aug 23
Prospectus supplement for primary offering
4:08pm
424B5
lzefn
31 Jul 23
Prospectus supplement for primary offering
5:13pm
ARS
a4q75g4x7n8x tyv
26 Apr 23
Annual report to shareholders
4:08pm
424B5
uco3 5kwdy
3 May 22
Prospectus supplement for primary offering
8:29pm
424B5
q2m1 k3qc
2 May 22
Prospectus supplement for primary offering
7:26am